Developer docs
API playgroundTry for free, no card

Search company profiles

AsclepiX Therapeutics

Full company profile

uuid0000jtb

Namestring
AsclepiX Therapeutics
Legal namestring
AsclepiX Therapeutics, Inc.
Websiteurl
asclepix.com
Company typeenum
Private
Founded yearint
2011
Short descriptiontext

AsclepiX Therapeutics is a Baltimore-based, clinical-stage biotech developing AXT107, a peptide therapeutic designed via computational biology for wet AMD and other neovascular retinal diseases. Pre-revenue and venture-backed, the company is advancing its lead candidate through a Phase 1/2a trial.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBaltimore, United States
HQ citystring
Baltimore
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
peptide therapeutics, retinal disease treatments, clinical-stage biotechnology, anti-angiogenic therapies, ophthalmic drug development
Industry1 code
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Ophthalmic Therapeutics
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

As a clinical-stage biotech company, AsclepiX Therapeutics is developing AXT107 for the treatment of neovascular retinal diseases including wet AMD. The company is pre-revenue and currently funded through venture capital. Future revenue will be generated through pharmaceutical product sales upon regulatory approval.

healio.com
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AsclepiX Therapeutics develops AXT107, a peptide-based therapeutic candidate designed via computational biology for the treatment of neovascular retinal diseases, with the primary focus on wet age-related macular degeneration (wet AMD). The company is currently advancing AXT107 through a Phase 1/2a clinical trial (DISCOVER study) to evaluate safety, tolerability, and efficacy. Beyond retinal disease, the company is also developing peptide therapeutics for cancer indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 1/2a DISCOVER study initiated to evaluate safety, tolerability, and efficacy of AXT107 in wet AMD patients
Product and service1 record
1AXT107
CategoryOphthalmic therapeutic candidate (peptide)
Description

AXT107 is a peptide-based therapeutic candidate developed using computational biology approaches for the treatment of neovascular retinal diseases, with primary focus on wet age-related macular degeneration (wet AMD). It is currently being evaluated in the Phase 1/2a DISCOVER clinical study for safety, tolerability, and efficacy in patients with wet AMD.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing suprachoroidal drug delivery for retinal and choroidal diseases. Direct peer in ocular drug delivery and retinal therapeutics.

TypeDirect peer
Description

Clinical-stage gene therapy company with ABBV-RGX-314 for wet AMD and diabetic retinopathy. Direct peer in retinal disease therapeutic development with novel modality.

TypeDirect peer
Description

Clinical-stage biotech developing sustained-release ocular therapeutics for retinal diseases and other eye conditions. Direct peer in the ophthalmology therapeutic space with similar stage and indication focus.

TypeEmerging player
Description

Clinical-stage cell therapy company with OpRegen for dry AMD and other retinal programs. Emerging peer in advanced therapy approaches for retinal disease.

TypeDirect peer
Description

Commercial-stage biotech with Syfovre for geographic atrophy and ongoing retinal disease programs. Direct peer in retinal therapeutics with a differentiated complement-cascade mechanism.

TypeDirect peer
Description

Clinical/commercial-stage company developing sustained-release ocular drug delivery (DURYSTA for glaucoma, pipeline in retinal diseases). Direct peer in ocular therapeutic delivery.

TypeEmerging player
Description

Clinical-stage biotech developing peptide therapeutics (including for ocular indications such as dry eye). Emerging peer based on peptide therapeutic modality rather than retinal disease focus.

TypeDirect peer
Description

Clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD. Direct peer in novel-modality retinal disease therapeutics.

TypeDirect peer
Description

Clinical-stage biotech developing novel therapeutics for retinal diseases, including wet AMD and diabetic macular edema. Direct peer in retinal disease drug development with anti-VEGF alternative approaches.

TypeDirect peer
Description

Retinal disease therapeutics developer (Izervay for geographic atrophy), acquired by Astellas in 2023. Direct peer in novel retinal therapeutics; provides benchmark exit valuation.

Market position
Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AsclepiX Therapeutics

Ophthalmic Therapeuticsasclepix.com

AsclepiX Therapeutics is a Baltimore-based, clinical-stage biotech developing AXT107, a peptide therapeutic designed via computational biology for wet AMD and other neovascular retinal diseases. Pre-revenue and venture-backed, the company is advancing its lead candidate through a Phase 1/2a trial.

AsclepiX Therapeutics firmographics

Firmographics
Name
AsclepiX Therapeutics
Legal name
AsclepiX Therapeutics, Inc.
Website
https://asclepix.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
AsclepiX Therapeutics is a Baltimore-based, clinical-stage biotech developing AXT107, a peptide therapeutic designed via computational biology for wet AMD and other neovascular retinal diseases. Pre-revenue and venture-backed, the company is advancing its lead candidate through a Phase 1/2a trial.
Ownership category
akta.pro rank

AsclepiX Therapeutics industry classification

Industry
Product category
Ophthalmic Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Peptide therapeutics
  • Retinal disease treatments
  • Clinical-stage biotechnology
  • Anti-angiogenic therapies
  • Ophthalmic drug development

Where AsclepiX Therapeutics is headquartered

Location

Headquarters

HQ city
Baltimore
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AsclepiX Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Revenue model

  1. Drug Development and Commercialization: As a clinical-stage biotech company, AsclepiX Therapeutics is developing AXT107 for the treatment of neovascular retinal diseases including wet AMD. The company is pre-revenue and currently funded through venture capital. Future revenue will be generated through pharmaceutical product sales upon regulatory approval.

Go-to-market motion1 record

AsclepiX Therapeutics product offering

Product offering

Core offering

AsclepiX Therapeutics develops AXT107, a peptide-based therapeutic candidate designed via computational biology for the treatment of neovascular retinal diseases, with the primary focus on wet age-related macular degeneration (wet AMD). The company is currently advancing AXT107 through a Phase 1/2a clinical trial (DISCOVER study) to evaluate safety, tolerability, and efficacy. Beyond retinal disease, the company is also developing peptide therapeutics for cancer indications.

Differentiator

Problem solved

Functional benefit

Products and services

  • AXT107 AXT107 is a peptide-based therapeutic candidate developed using computational biology approaches for the treatment of neovascular retinal diseases, with primary focus on wet age-related macular degeneration (wet AMD). It is currently being evaluated in the Phase 1/2a DISCOVER clinical study for safety, tolerability, and efficacy in patients with wet AMD.

Quantifiable outcome

  • Phase 1/2a DISCOVER study initiated to evaluate safety, tolerability, and efficacy of AXT107 in wet AMD patients

Companies that use AsclepiX Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

AsclepiX Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

AsclepiX Therapeutics partnerships and signals

Strategic signal

Scale indicators3 records

AsclepiX Therapeutics competitors and assessment

Company assessment

Direct peers

  • Clearside Biomedical: Clinical-stage biotech developing suprachoroidal drug delivery for retinal and choroidal diseases. Direct peer in ocular drug delivery and retinal therapeutics.
  • REGENXBIO: Clinical-stage gene therapy company with ABBV-RGX-314 for wet AMD and diabetic retinopathy. Direct peer in retinal disease therapeutic development with novel modality.
  • Ocular Therapeutix: Clinical-stage biotech developing sustained-release ocular therapeutics for retinal diseases and other eye conditions. Direct peer in the ophthalmology therapeutic space with similar stage and indication focus.
  • Apellis Pharmaceuticals: Commercial-stage biotech with Syfovre for geographic atrophy and ongoing retinal disease programs. Direct peer in retinal therapeutics with a differentiated complement-cascade mechanism.
  • EyePoint Pharmaceuticals: Clinical/commercial-stage company developing sustained-release ocular drug delivery (DURYSTA for glaucoma, pipeline in retinal diseases). Direct peer in ocular therapeutic delivery.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing ADVM-022 (ixoberogene soroparvovec) for wet AMD. Direct peer in novel-modality retinal disease therapeutics.
  • Kodiak Sciences: Clinical-stage biotech developing novel therapeutics for retinal diseases, including wet AMD and diabetic macular edema. Direct peer in retinal disease drug development with anti-VEGF alternative approaches.
  • Iveric Bio: Retinal disease therapeutics developer (Izervay for geographic atrophy), acquired by Astellas in 2023. Direct peer in novel retinal therapeutics; provides benchmark exit valuation.

Emerging players

  • Lineage Cell Therapeutics: Clinical-stage cell therapy company with OpRegen for dry AMD and other retinal programs. Emerging peer in advanced therapy approaches for retinal disease.
  • Palatin Technologies: Clinical-stage biotech developing peptide therapeutics (including for ocular indications such as dry eye). Emerging peer based on peptide therapeutic modality rather than retinal disease focus.

Market position

Customer concentration

AsclepiX Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AsclepiX Therapeutics leadership team

Management profile

Number of profiles

Profiles3 records

AsclepiX Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AsclepiX Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AsclepiX Therapeutics

What does AsclepiX Therapeutics do?

AsclepiX Therapeutics develops AXT107, a peptide-based therapeutic candidate designed via computational biology for the treatment of neovascular retinal diseases, with the primary focus on wet age-related macular degeneration (wet AMD). The company is currently advancing AXT107 through a Phase 1/2a clinical trial (DISCOVER study) to evaluate safety, tolerability, and efficacy. Beyond retinal disease, the company is also developing peptide therapeutics for cancer indications.

Is AsclepiX Therapeutics a public or private company?

AsclepiX Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was AsclepiX Therapeutics founded?

AsclepiX Therapeutics was founded in 2011. It employs 1 to 10 people.

Where is AsclepiX Therapeutics based?

AsclepiX Therapeutics is headquartered in Baltimore, United States, in the North America region.

How does AsclepiX Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are AsclepiX Therapeutics's main competitors?

Direct peers on record are Clearside Biomedical, REGENXBIO, Ocular Therapeutix, Apellis Pharmaceuticals, EyePoint Pharmaceuticals, Adverum Biotechnologies, Kodiak Sciences and Iveric Bio. Emerging players are Lineage Cell Therapeutics and Palatin Technologies.

Does AsclepiX Therapeutics have an API?

No public API is recorded for AsclepiX Therapeutics.

What industry is AsclepiX Therapeutics in?

AsclepiX Therapeutics's product category is Ophthalmic Therapeutics. Its primary akta.pro industry code is HLAHAIAL, Ocular Drug Delivery Devices (Eye Droppers/Inserts). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DAsclepiX Therapeutics, Inc. filed a Notice of Exempt Offering of Securities with the SEC, indicating an offering amount of $12,544,498, of which $10,044,498 has already been sold. The offering is not intended to last more than one year and is not related to any business combination transaction. The filing includes detailed information on executives and the use of proceeds from the offering.Pulse 2.0AsclepiX Therapeutics: $10 Million Raised For Advancing Phase 1/2a Clinical Study of AXT107AsclepiX Therapeutics raised $10 million in a Series A-3 financing round led by Perceptive Advisors. The funds will advance the Phase 1/2a DISCOVER study of AXT107, a microparticulate suspension for wet AMD, with enrollment expected in early 2024.GlobeNewswireAsclepiX Therapeutics Raises $10 Million to Advance Phase 1/2a Clinical Study of AXT107AsclepiX Therapeutics has secured $10 million in Series A-3 financing to advance the Phase 1/2a clinical study of its lead candidate, AXT107, for treating wet age-related macular degeneration. The funding, led by Perceptive Advisors with participation from existing and new investors, will support the upcoming DISCOVER study which aims to evaluate the safety and tolerability of three doses of the drug. Enrollment in the clinical trial is scheduled to begin in early 2024.FinSMEsAsclepiX Therapeutics Raises $10M in Series A-3 FundingAsclepiX Therapeutics raised $10 million in Series A-3 funding, a round led by Perceptive Advisors with participation from existing and new investors. The company intends to use the capital to expand its operations and research and development efforts for retinal disease treatments.Daily Medical NewsAsclepiX secures $10 million in Series A-3 financing roundAsclepiX Therapeutics has secured $10 million in Series A-3 financing to advance the development of its lead clinical candidate, AXT107, for treating neovascular retinal diseases. The funding, led by Perceptive Advisors with participation from Hibiscus Capital Management and Rapha Capital, will support a phase 1/2a trial investigating the drug's safety and tolerability for wet age-related macular degeneration.GlobeNewswireAsclepiX Therapeutics partners with Notal Vision on Home OCT remote monitoring in DME and AMD clinical trialsNotal Vision will provide AsclepiX Therapeutics with Home OCT monitoring services for its AXT107 phase 1 trials in diabetic macular edema and wet AMD. The device enables daily self-imaging, with data transmitted to Notal Health Cloud for AI analysis. The partnership aims to enrich trial datasets and reduce office visit burden.Pulse 2.0Biopharmaceutical Company AsclepiX Therapeutics Raises $35 MillionAsclepiX Therapeutics raised $35 million in Series A funding led by Perceptive Advisors, with participation from existing investors. The proceeds will fund Phase 1/2a clinical trials of AXT107 for diabetic macular edema, wet AMD, and RVO. The company expects to initiate trials in the second half of 2020.TechnicalAsclepiX Therapeutics eyeing clinical trials after closing $35M Series AAsclepiX Therapeutics raised $35 million in a Series A round led by Perceptive Xontogeny Venture Fund to fund clinical trials of its investigational drug AXT107 for eye diseases like diabetic macular edema and wet AMD. The company plans Phase 1 and 2a trials, with the first trials set to begin later this year.